48 studies on PT-141 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 1,400 published PT-141 COA source records from third-party laboratories, covering 535 publicly attributable vendor identities. Across 1,246 records with positive numeric purity, the arithmetic mean is 99.73%. 4 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 2 positive purity results are below 90%; 100 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-15. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $9.17 | $8.00–$10.50 | $0.92 | 3 sources · 3 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-15. Aggregate calculated: 2026-10-18T06:20:48.215147+00:00. Calculation time is not a laboratory observation date.
Within that total, 378 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 23 | 99.82% | 0 of 21 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #2 | 21 | 99.87% | 0 of 19 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #3 | 15 | 99.72% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120331 (99.97%) · #120438 (99.74%) · #120218 (99.92%) · #120169 (99.5%) · #119504 (99.6%) · #119530 (99.91%)
This study significantly advances the field by demonstrating that **tailored midsized macrocycles can achieve high selectivity for specific melanocortin receptors**, particularly `MC4R`. For peptide users and biohacke…
This systematic review consolidates the current clinical trial evidence for pharmacological treatments of **Hypoactive Sexual Desire Disorder (HSDD)**, offering a clearer picture for clinicians and patients. **Underst…
For clinicians and users, this guidance highlights a critical data gap and advises a conservative approach. **The primary takeaway is to use bremelanotide with caution during breastfeeding, particularly when nursing a…
This research highlights the significant therapeutic potential of melanocortin peptides in addressing unmet medical needs. The development of MTI could offer a novel, preventative approach to skin cancer through induc…
**Bremelanotide's ability to improve self-reported desire and intercourse-related arousal satisfaction without requiring a physiological vasocongestion signal** suggests its mechanism is primarily central — a meaningf…
**Central MC receptor activation via PT-141 offers a mechanistically distinct alternative to PDE5 inhibitors**, potentially benefiting patients who fail vascular-targeted therapies or who present primarily with reduce…
**Bremelanotide's central mechanism of action** — activating `melanocortin receptors` in the hypothalamus rather than relaxing peripheral vasculature — means it avoids the hypotensive liability that limits PDE5 inhibi…
**Bremelanotide's CNS mechanism differentiates it from all currently available FSD treatments**, which predominantly target hormonal or vascular pathways — making it a potentially valuable addition where those approac…
This review highlights the untapped potential of targeting the central nervous system for treating sexual dysfunction, offering a complementary approach to existing peripheral treatments. By modulating key neurotransm…
This retraction highlights the critical importance of research integrity and transparency in scientific publishing. Unverified or fraudulent data can mislead future research and potentially harm patients if treatments…
**Clinicians managing sildenafil non-responders now have preliminary randomized evidence for a mechanistically distinct intranasal peptide option.** Because bremelanotide acts centrally via `MC3R`/`MC4R` rather than t…
This review highlights a paradigm shift in treating male sexual dysfunction, moving beyond peripheral mechanisms to target the central nervous system. By modulating neurohormones and neurotransmitters, these agents co…
**Bremelanotide's appearance in a multi-compound clinical-trials digest** places it on the map of agents that had sufficiently advanced development programs to warrant monitoring by major drug-intelligence platforms. …
The review identified nasal apomorphine and bremelanotide as the most promising centrally acting agents with significant potential for future approval in erectile dysfunction (ED) treatment. While several other agents…
This review consolidates the evidence for melanocortin agonists as a viable treatment class for both male and female sexual dysfunctions, offering a centrally-acting alternative to peripheral-focused drugs. For indivi…
This review consolidates the neurobiological framework for understanding **HSDD**, shifting the focus from purely psychological or hormonal models to a central nervous system-based approach. For clinicians and patient…
This study provides strong evidence that bremelanotide is a safe, effective, and well-tolerated treatment for female sexual dysfunctions in premenopausal women. The significant improvements in satisfying sexual events…
This review provides a crucial overview for clinicians and patients navigating the difficult landscape of **HSDD** treatment. It positions bremelanotide (PT-141) within a broader context of available therapies, sugges…
This review reinforces the understanding that female sexual desire is not just hormonal but is deeply rooted in central nervous system neurochemistry, particularly the balance between serotonin and dopamine. For indiv…
**For individuals experiencing FSIAD, this review underscores that while pharmacological options like flibanserin exist, their standalone clinical impact is often modest.** This suggests that relying solely on medicat…
This review provides a structured clinical framework for addressing HSDD, a condition often overlooked. For clinicians and patients, it clarifies the diagnostic pathway and summarizes the limited therapeutic landscape…
This study provides robust validation for the **1.75 mg dose of bremelanotide** as an effective treatment for premenopausal women with HSDD. The multiple responder analyses offer a sophisticated framework for interpre…
The approval of bremelanotide represents a pivotal advancement in addressing a significant unmet medical need for women experiencing HSDD. Its unique profile as a self-administered, on-demand subcutaneous therapy offe…
This research provides critical data for the development of alternative bremelanotide formulations, indicating that standard oral administration is likely ineffective. For users or developers, this strongly suggests t…
This validation provides a new, reliable tool for both researchers and clinicians to more accurately measure sexual desire in women with HSDD. For individuals using or considering peptides like bremelanotide, the EDQ …
This research highlights the critical role of advanced analytical techniques in combating the illegal trade of unapproved drugs, which often pose significant health risks to users. The successful identification of mel…
This review clarifies the specific neurobiological target for bremelanotide, moving beyond a general understanding to pinpoint its action on `MC4R` in the hypothalamus and subsequent dopamine release. For clinicians a…
This study's qualitative data provides crucial context to the quantitative efficacy demonstrated in the main clinical trials. For clinicians and patients, it clarifies that bremelanotide's effects are not merely stati…
This re-analysis provides a crucial counter-narrative to the initial positive reporting on bremelanotide for **HSDD**. For clinicians and potential users, it highlights that the drug's modest benefits on desire may no…
This critical analysis underscores the urgent need for reconsideration of regulatory decisions regarding these drugs, given their questionable efficacy. The findings highlight how politicized industry-sponsored advoca…
This comprehensive review provides a vital resource for healthcare professionals, offering much-needed clarity on the diverse medical treatments available for Female Sexual Dysfunction (FSD). By clearly outlining spec…
This review provides crucial guidance for clinicians and individuals managing **hypertension** while experiencing **FSD**. **Selecting antihypertensive agents that do not exacerbate, or even improve, sexual function i…
This review provides a strong evidence base for clinicians, confirming that pharmacologic interventions are safe and effective tools to improve sexual desire and satisfaction in individuals experiencing sexual dysfunc…
This review consolidates extensive research, providing a clear roadmap for future drug development targeting the melanocortin system. The identification of potent and selective ligands for MC3R and MC4R offers novel a…
This review profoundly underscores the immense and expanding potential of the central melanocortin system as a drug target for a wide array of metabolic and behavioral disorders. The established safety profile and cli…
This comprehensive review is crucial for advancing clinical practice in managing female sexual dysfunction, a condition affecting a significant number of women. By consolidating information on both established and nov…
If successful, the findings from this Phase 3 trial could demonstrate that Bremelanotide offers a significant new treatment option for premenopausal women suffering from HSDD, a condition with substantial impact on qu…
The provided clinical trial registration record, which concluded in May 2007, confirms that the study successfully completed its 8-week duration as planned. However, specific efficacy and safety results, including det…
Free, no account — handy when you're working with PT-141.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account